Pharsight

Drugs that contain Daptomycin

1. List of Cubicin drug patents

CUBICIN's oppositions filed in EPO
CUBICIN Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003673 CUBIST PHARMS LLC Daptomycin for the treatment of biofilm and catheter salvage
Sep, 2028

(5 years from now)

US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods
Nov, 2030

(7 years from now)

Market Authorisation Date: 12 September, 2003

Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of CUBICIN before it's patent expiration?
More Information on Dosage

CUBICIN family patents

9

United States

4

Japan

3

China

2

Peru

2

Taiwan, Province of China

2

Canada

2

Chile

2

European Union

1

Portugal

1

Turkey

1

Singapore

1

Russia

1

Spain

1

Brazil

1

Croatia

1

Costa Rica

1

Colombia

1

New Zealand

1

Dominican Republic

1

Argentina

1

Mexico

1

Lithuania

1

Cyprus

1

Hungary

1

Slovenia

1

Israel

1

Poland

1

Australia

1

Ecuador

1

RS

1

Denmark

2. List of Daptomycin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357535 HOSPIRA INC Daptomycin formulations and uses thereof
Sep, 2033

(10 years from now)

US9655946 HOSPIRA INC Daptomycin formulations and uses thereof
Sep, 2033

(10 years from now)

Market Authorisation Date: 21 June, 2021

Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administering the formulation as recited in claim 12; Treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the formulation of daptomycin as recited in claim 18

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

DAPTOMYCIN family patents

7

United States

3

New Zealand

2

Australia

2

European Union

1

Germany

1

Singapore

1

Spain

1

Brazil

1

IB

1

Mexico

1

Morocco

1

Hong Kong

1

Tunisia

1

South Africa

1

Canada

1

Hungary

1

Saudi Arabia

1

Israel

1

Chile

1

Denmark

3. List of Dapzura Rt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173189 BAXTER HLTHCARE CORP Daptomycin formulations containing a combination of sorbitol and mannitol
Mar, 2041

(17 years from now)

Market Authorisation Date: 25 January, 2022

Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

DAPZURA RT family patents

5

United States

1

Australia

1

Canada

1

China

1

Brazil

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic